TWI241302B - Lactam compounds and pharmaceutical use thereof - Google Patents
Lactam compounds and pharmaceutical use thereof Download PDFInfo
- Publication number
- TWI241302B TWI241302B TW090129582A TW90129582A TWI241302B TW I241302 B TWI241302 B TW I241302B TW 090129582 A TW090129582 A TW 090129582A TW 90129582 A TW90129582 A TW 90129582A TW I241302 B TWI241302 B TW I241302B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- substituent
- diabetic
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- -1 Lactam compounds Chemical class 0.000 title abstract description 8
- 125000001424 substituent group Chemical group 0.000 abstract description 28
- 125000000217 alkyl group Chemical group 0.000 abstract description 9
- 125000003118 aryl group Chemical group 0.000 abstract description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 9
- 150000003839 salts Chemical class 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 abstract description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract description 4
- 125000003277 amino group Chemical group 0.000 abstract description 4
- 125000005843 halogen group Chemical group 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract description 2
- 206010063547 Diabetic macroangiopathy Diseases 0.000 abstract description 2
- 208000008589 Obesity Diseases 0.000 abstract description 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract description 2
- 125000000304 alkynyl group Chemical group 0.000 abstract description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 2
- 208000033679 diabetic kidney disease Diseases 0.000 abstract description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000003609 aryl vinyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 125000002723 alicyclic group Chemical group 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000367175 | 2000-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI241302B true TWI241302B (en) | 2005-10-11 |
Family
ID=18837660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW090129582A TWI241302B (en) | 2000-12-01 | 2001-11-29 | Lactam compounds and pharmaceutical use thereof |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US7153850B2 (https=) |
| EP (1) | EP1346993B1 (https=) |
| JP (2) | JP3826400B2 (https=) |
| KR (1) | KR100826818B1 (https=) |
| CN (2) | CN1269818C (https=) |
| AT (1) | ATE446297T1 (https=) |
| AU (3) | AU1850202A (https=) |
| BG (1) | BG107857A (https=) |
| BR (1) | BR0115852A (https=) |
| CA (1) | CA2430124C (https=) |
| CZ (1) | CZ20031520A3 (https=) |
| DE (1) | DE60140270D1 (https=) |
| ES (1) | ES2331299T3 (https=) |
| HU (1) | HUP0400806A3 (https=) |
| IL (1) | IL156158A0 (https=) |
| MX (1) | MXPA03004876A (https=) |
| NO (1) | NO325401B1 (https=) |
| NZ (1) | NZ526164A (https=) |
| PL (1) | PL362835A1 (https=) |
| RU (1) | RU2287530C2 (https=) |
| SK (1) | SK6582003A3 (https=) |
| TW (1) | TWI241302B (https=) |
| UA (1) | UA76969C2 (https=) |
| WO (1) | WO2002044180A1 (https=) |
| YU (1) | YU42603A (https=) |
| ZA (1) | ZA200304100B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1850202A (en) * | 2000-12-01 | 2002-06-11 | Ajinomoto Kk | Lactam compounds and medicinal use thereof |
| CN101822834A (zh) | 2003-02-07 | 2010-09-08 | 味之素株式会社 | 糖尿病治疗药 |
| WO2005042536A1 (ja) * | 2003-10-31 | 2005-05-12 | Ajinomoto Co., Inc. | 複素環を有する新規縮合多環式化合物及びその医薬用途 |
| JPWO2005068467A1 (ja) | 2004-01-14 | 2007-12-27 | 味の素株式会社 | 新規縮環化合物 |
| WO2006040036A1 (en) * | 2004-10-13 | 2006-04-20 | F. Hoffmann-La Roche Ag | Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer |
| BRPI0610034A2 (pt) | 2005-04-28 | 2011-10-18 | Ajinomoto Kk | composto, agente de icremento do transporte de açúcar, agente hipoglicêmico, agente para prevenção e/ou tratamento de uma doença, medicamento, composição farmacêutica , uso do composto, e, método de preparação para o composto |
| WO2008126920A1 (ja) | 2007-04-11 | 2008-10-23 | Ajinomoto Co., Inc. | 糖尿病治療薬 |
| WO2008136392A1 (ja) * | 2007-04-27 | 2008-11-13 | Ajinomoto Co., Inc. | 経口投与用製剤 |
| WO2008139575A1 (ja) * | 2007-04-27 | 2008-11-20 | Ajinomoto Co., Inc. | 経口投与用製剤 |
| WO2008139574A1 (ja) * | 2007-04-27 | 2008-11-20 | Ajinomoto Co., Inc. | ラクタム化合物の結晶形およびその製造方法 |
| CN101619041B (zh) * | 2008-07-02 | 2012-07-04 | 重庆华邦制药股份有限公司 | 一种二酮基含氮环化合物的合成方法及其中间体 |
| JP2012180283A (ja) * | 2009-07-02 | 2012-09-20 | Ajinomoto Co Inc | ラクタム化合物の製造方法およびその製造中間体 |
| JP2012180282A (ja) * | 2009-07-02 | 2012-09-20 | Ajinomoto Co Inc | ラクタム化合物の製造方法およびその製造中間体 |
| EP3238723B1 (en) * | 2014-12-22 | 2020-02-05 | EA Pharma Co., Ltd. | Drug for treating disorders of corneal epithelium |
| AU2017208970A1 (en) | 2016-01-18 | 2018-08-02 | Arisan Therapeutics | Adamatane derivatives for the treatment of filovirus infection |
| WO2019018185A1 (en) | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS |
| MX2021008937A (es) * | 2019-01-23 | 2021-11-12 | Glycolysis Biomed Co Ltd | Compuestos de beta-lactama o sales de los mismos para su uso en la prevencion o tratamiento de accion prolongada del trastorno del metabolismo de la glucosa. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US189597A (en) * | 1877-04-17 | Improvement in portable wash-stands | ||
| US48847A (en) * | 1865-07-18 | Improvement in vessels for reception and transportation of night-soil | ||
| GB8720414D0 (en) * | 1987-08-28 | 1987-10-07 | Roussel Lab Ltd | Chemical compounds |
| US5719296A (en) * | 1995-10-30 | 1998-02-17 | Merck & Co., Inc. | Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins |
| BR9811559A (pt) | 1997-07-30 | 2000-09-12 | American Home Prod | Agonistas tricìclicos de vasopressina |
| JP4204657B2 (ja) | 1997-12-05 | 2009-01-07 | 有限会社ケムフィズ | 糖尿病の予防・治療剤 |
| AU1850202A (en) | 2000-12-01 | 2002-06-11 | Ajinomoto Kk | Lactam compounds and medicinal use thereof |
| CN101822834A (zh) * | 2003-02-07 | 2010-09-08 | 味之素株式会社 | 糖尿病治疗药 |
-
2001
- 2001-11-29 AU AU1850202A patent/AU1850202A/xx active Pending
- 2001-11-29 PL PL01362835A patent/PL362835A1/xx not_active Application Discontinuation
- 2001-11-29 WO PCT/JP2001/010435 patent/WO2002044180A1/ja not_active Ceased
- 2001-11-29 SK SK658-2003A patent/SK6582003A3/sk unknown
- 2001-11-29 NZ NZ526164A patent/NZ526164A/en unknown
- 2001-11-29 AT AT01998549T patent/ATE446297T1/de not_active IP Right Cessation
- 2001-11-29 CN CNB018223559A patent/CN1269818C/zh not_active Expired - Fee Related
- 2001-11-29 AU AU2002218502A patent/AU2002218502B2/en not_active Ceased
- 2001-11-29 CZ CZ20031520A patent/CZ20031520A3/cs unknown
- 2001-11-29 DE DE60140270T patent/DE60140270D1/de not_active Expired - Lifetime
- 2001-11-29 CA CA2430124A patent/CA2430124C/en not_active Expired - Fee Related
- 2001-11-29 ES ES01998549T patent/ES2331299T3/es not_active Expired - Lifetime
- 2001-11-29 YU YU42603A patent/YU42603A/sh unknown
- 2001-11-29 HU HU0400806A patent/HUP0400806A3/hu unknown
- 2001-11-29 EP EP01998549A patent/EP1346993B1/en not_active Expired - Lifetime
- 2001-11-29 KR KR1020037007327A patent/KR100826818B1/ko not_active Expired - Fee Related
- 2001-11-29 UA UA2003055026A patent/UA76969C2/uk unknown
- 2001-11-29 IL IL15615801A patent/IL156158A0/xx unknown
- 2001-11-29 RU RU2003116126/04A patent/RU2287530C2/ru not_active IP Right Cessation
- 2001-11-29 BR BR0115852-0A patent/BR0115852A/pt not_active Application Discontinuation
- 2001-11-29 MX MXPA03004876A patent/MXPA03004876A/es active IP Right Grant
- 2001-11-29 JP JP2002546550A patent/JP3826400B2/ja not_active Expired - Lifetime
- 2001-11-29 TW TW090129582A patent/TWI241302B/zh not_active IP Right Cessation
- 2001-11-29 CN CN200610095903A patent/CN100577651C/zh not_active Expired - Fee Related
-
2003
- 2003-05-27 ZA ZA200304100A patent/ZA200304100B/en unknown
- 2003-05-28 NO NO20032439A patent/NO325401B1/no not_active IP Right Cessation
- 2003-05-29 BG BG107857A patent/BG107857A/bg unknown
- 2003-06-02 US US10/449,774 patent/US7153850B2/en not_active Expired - Fee Related
-
2006
- 2006-04-06 US US11/398,675 patent/US7326701B2/en not_active Expired - Fee Related
- 2006-05-12 JP JP2006134026A patent/JP4505753B2/ja not_active Expired - Fee Related
- 2006-11-24 AU AU2006241377A patent/AU2006241377B2/en not_active Ceased
-
2007
- 2007-11-30 US US11/948,288 patent/US7632830B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI241302B (en) | Lactam compounds and pharmaceutical use thereof | |
| JP3274865B2 (ja) | ５−ｈｔレセプター拮抗物質としてのピペラジン誘導体 | |
| Adams et al. | Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity | |
| CA2516370C (en) | A process of preparing imatinib and imatinib prepared thereby | |
| CA2958095C (en) | 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof | |
| JP3819024B2 (ja) | 置換ピリミジン化合物およびその使用 | |
| IL291590B1 (en) | Novel modified quinoline-8-carbonitrile compounds with androgen receptor unblocking activity and their uses | |
| CA2613303A1 (en) | An oxime derivative for use as a glucokinase activator | |
| MX2025012216A (es) | Antagonistas del receptor de polipeptido insulinotropico dependiente de glucosa y usos de estos | |
| CA2474104A1 (en) | N-oxides of n-phenyl-2-pyrimidine-amine derivatives | |
| KR960703917A (ko) | 축합된 벤즈아제핀 유도체 및 이를 함유하는 약제학적 조성물(Fused benzazepine derivative and pharmaceutical composition containing the same) | |
| ATE303387T1 (de) | Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus | |
| MX2010006182A (es) | Derivados de isoxazolo-piridazina. | |
| KR920014472A (ko) | {ω-[4-(2-피리미디닐)-1-피페라지닐]알킬}-1H-아졸 유도체의 인식기능 장해 치료를 위한 의약품 제조에의 이용 | |
| TWI262917B (en) | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same | |
| AR035722A1 (es) | Derivados de indol, procesos para su preparacion, composiciones farmaceuticas que los comprenden y el uso de dichos compuestos para la produccion de medicamentos | |
| CA2522435A1 (en) | Inhibitors of akt activity | |
| UA70966C2 (uk) | Піримідини, що інгібують реплікацію віл | |
| AU2005335298C1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| WO2007054770A3 (en) | Pyrazole derivatives and their medical use | |
| Bloom et al. | Thiourea inhibitors of herpes viruses. Part 1: bis-(aryl) thiourea inhibitors of CMV | |
| PE20060771A1 (es) | Profarmaco de amida de gemcitabina y composiciones que lo contienen | |
| CA2462903A1 (en) | Beta-lactamyl vasopressin v1a antagonists | |
| JP2006213732A5 (https=) | ||
| MY143578A (en) | Piperazinediones as oxytocin receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |